Method for treating aids-associated dementia
US5877222A · kind A · utility
14Cited by
5References
4Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Jul 19, 1996 |
| Grant date | Mar 2, 1999 |
| Priority date | — |
| Expiry date | Jul 19, 2016 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K33/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention comprises inhibiting expression of TNF-.alpha. by administering an effective amount of a stabilized activated oxygen in a matrix of chlorite ions. Preferably, a pharmaceutically acceptable formulation of tetrachlorodecaoxide is used, and more preferably, WF-10. An effective amount of WF-10 comprises up to about 0.5 ml/kg. Another embodiment of the invention is a method of treating AIDS-associated dementia comprising the step of administering to a human an amount of a stabilized activated oxygen in a matrix of chlorite ions sufficient to inhibit production of TNF-.alpha..
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.